Expanded Community MedTech Prescriptions to be Swiftly Implemented, Detailing Specific Treatment Plans
The Department of Health and Social Care (DHSC) has launched a new project aimed at **standardising local community prescribing formularies for MedTech products** in England. This initiative seeks to create a consistent, streamlined approach across the country for the prescribing of medical technologies in local community settings.
**Purpose**
The primary objective of this project is **standardisation**. Currently, prescribing formularies for MedTech products vary widely at the local level, leading to confusion among healthcare professionals and patients. By harmonising these formularies, the project aims to simplify the decision-making process, ensuring quicker and more equitable access to appropriate MedTech devices.
This initiative aligns with the broader NHS 10 Year Plan and government health goals, empowering patients and professionals by providing clearer guidance and reducing local disparities in available medical technology options.
**Implications**
A standardised formulary could lead to **better resource utilisation**. Commissioning and procurement could become more efficient, potentially lowering costs through economies of scale and reducing duplication.
The project also emphasises the importance of **enhanced quality and safety**. Consistent formularies promote the use of vetted, clinically effective MedTech products, which can improve patient outcomes and safety.
Furthermore, a national-standard approach could **facilitate innovation adoption**. By providing a clear pathway to inclusion in prescribing formularies, the project could simplify the introduction of new, innovative MedTech products into the NHS.
However, transitioning to a standardised formulary might require **adaptation at the local service level**, including re-education and system changes.
**Considerations**
The project considers a wide range of factors, including clinical effectiveness, the availability of real-world evidence, supporting self-care, system savings, reducing health inequalities, patient choice, diversity of users, quality of information for patients, impact of personal circumstances, adherence to use of medical devices, accessibility of medical devices, inclusion of medical device characteristics in Health Technology Assessments, influence of sex and gender in clinical trials of medical devices, software as a medical device, medical devices used for patient self-testing, and medical devices safety.
**Engagement and Timeline**
Industry, clinicians, patients, and their advocates, as well as those with expertise in assessing whole system costs, are encouraged to proactively engage with this process. The project is being launched by the DHSC's MedTech and Innovation Directorate.
The project is scheduled to complete with the publication of the new guidance in April 2026, and production of the new formularies by all local NHS systems in England is expected by April 2027.
Chris Whitehouse, a political consultant and expert on medical technology policy and regulation, serves as the chair of the Urology Trade Association and governor of the Anscombe Bioethics Centre. Whitehouse Communications is an advisor to MedTech suppliers.
Real world evidence and case studies are considered essential for the process to avoid adversely affecting patients due to over-reliance on randomised control trials. The project also addresses the influence of sex and gender in clinical trials of medical devices, as well as the safety of medical devices.
This article was prepared using AI technology, reflecting the increasing role of technology in shaping healthcare policies and practices.
- The new project from the Department of Health and Social Care (DHSC) aims to create a standardised local community prescribing formulary for medical technologies (MedTech products), aligning with the NHS 10 Year Plan and health goals.
- A standardised formulary could lead to better resource utilisation, potentially lowering costs through economies of scale and reducing duplication in commissioning and procurement processes.
- The project emphasises the importance of enhanced quality and safety, promoting the use of clinically effective MedTech products for improved patient outcomes and safety.
- The national-standard approach could facilitate innovation adoption by providing a clear pathway to inclusion in prescribing formularies, simplifying the introduction of new, innovative MedTech products into the NHS.
- Transitioning to a standardised formulary may require adaptation at the local service level, including re-education and system changes, given the wide range of factors considered, ranging from clinical effectiveness to medical devices safety.
